| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.34 | 4e-22 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-09 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.17 | 6e-08 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-07 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.13 | 5e-05 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.14 | 9e-05 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.0002 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0004 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.001 |